We are live on ! Find out more
Deerfield Management

Deerfield Management Portfolio holdings

AUM $6.47B Turnover 21.35%
1-Year Est. Return 71.25%
 

Deerfield Management is an investment firm dedicated to healthcare, backing therapeutics, medical device, diagnostics and digital health companies at every stage, from startups to mature public businesses. Arnold Snider, a former Tiger Management managing director and Kidder Peabody pharmaceutical analyst, founded the firm in 1994 and retired in 2005. James Flynn joined in 2000 and later became chief executive. Its first healthcare innovations fund, raised in 2015, aimed at scientific advances that could lead to new treatments for genetic diseases, cancer and orphan diseases. In 2020 Deerfield took over Melinta Therapeutics, swapping secured debt for all of its equity after Melinta filed for bankruptcy. Its in-house research arm, Deerfield Discovery and Development, moves early-stage therapies from scientific discovery into the clinic.

This Fund
S&P 500
This Quarter Est. Return
+2.62%
1 Year Est. Return
+71.25%
3 Year Est. Return
+262.82%
5 Year Est. Return
+342.14%
10 Year Est. Return
+1,890.99%
AUM
$1.87B
AUM Growth
-$718M
Cap. Flow
-$899M
Cap. Flow %
-47.95%
Top 10 Hldgs %
41.84%
Holding
112
New
12
Increased
13
Reduced
41
Closed
27
Avg Time Held Equity + Options
1.2 years
Top 10 Avg Time Held Equity + Options
0.9 years
Top 20 Avg Time Held Equity + Options
0.9 years
Avg Time Held Equity only
1.3 years
Top 10 Avg Time Held Equity only
0.9 years
Top 20 Avg Time Held Equity only
0.9 years

Top Buys

Rank Stock Value
1
GKOS icon
Glaukos
GKOS
+$30.8M
2
XENT
Intersect ENT
XENT
+$26.9M
3
MNK
Mallinckrodt
MNK
+$19.7M
4
PDCO icon
Patterson Companies
PDCO
+$17.7M
5
MCK icon
McKesson
MCK
+$13.1M

Sector Composition

Rank Sector Weight
1 Healthcare 77.83%
2 Miscellaneous 20.43%
3 Financials 1.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
AVXS
1
DELISTED
AveXis
AVXS
$190M 10.12%
2,308,130
+71,429
+3% +$5.36M
2016 Q1
5 quarters
HZNP
2
DELISTED
Horizon Therapeutics
HZNP
$107M 5.7%
8,998,413
-1,946,575
-18% -$24.2M
2013 Q4
14 quarters
NXTM
3
DELISTED
NxStage Medical
NXTM
$96.1M 5.13%
3,833,330
+89,179
+2% +$2.21M
2013 Q2
16 quarters
GILD icon
4
Gilead Sciences
GILD
$206B
$66.4M 3.54%
938,515
-264,485
-22% -$17.6M
2017 Q1
1 quarter
GILD icon
5
CALL
Gilead Sciences
GILD
$206B
$53.1M 2.83%
+750,000
New +$49.9M
2017 Q2
0 quarters
VTRS icon
6
Viatris
VTRS
$22.5B
$53.1M 2.83%
1,367,119
-675,105
-33% -$25.9M
2015 Q1
9 quarters
MNK
7
DELISTED
Mallinckrodt
MNK
$52.8M 2.82%
1,178,605
+449,656
+62% +$19.7M
2016 Q4
2 quarters
MCK icon
8
McKesson
MCK
$123B
$51.9M 2.77%
315,417
+86,417
+38% +$13.1M
2017 Q1
1 quarter
AERI
9
DELISTED
Aerie Pharmaceuticals
AERI
$50.5M 2.69%
961,147
+165,404
+21% +$7.7M
2013 Q4
14 quarters
AVDL
10
DELISTED
Avadel Pharmaceuticals
AVDL
$40.3M 2.15%
3,655,494
-417,315
-10% -$4.19M
2013 Q2
16 quarters
GKOS icon
11
Glaukos
GKOS
$14B
$37.1M 1.98%
894,551
+714,551
+397% +$30.8M
2016 Q2
4 quarters
GWPH
12
DELISTED
GW Pharmaceuticals
GWPH
$36.1M 1.92%
359,983
-65,562
-15% -$7.06M
2015 Q1
9 quarters
XENT
13
DELISTED
Intersect ENT
XENT
$33.2M 1.77%
+1,189,577
New +$26.9M
2017 Q2
0 quarters
BOLD icon
14
DELISTED
Audentes Therapeutics
BOLD
$33.1M 1.76%
1,729,268
+325,615
+23% +$5.2M
2016 Q3
3 quarters
LCI
15
DELISTED
Lannett
LCI
$31.1M 1.66%
380,989
-82,485
-18% -$7.19M
2016 Q4
2 quarters
EDIT icon
16
Editas Medicine
EDIT
$253M
$28.7M 1.53%
1,709,400
– –
2016 Q1
5 quarters
NVRO icon
17
DELISTED
Nevro
NVRO
$28M 1.49%
376,308
-26,690
-7% -$2.14M
2016 Q3
3 quarters
DBVT icon
18
DBV Technologies
DBVT
$567M
$23.8M 1.27%
66,520
-107,803
-62% -$36.8M
2014 Q4
10 quarters
PTLA
19
DELISTED
Portola Pharmaceuticals
PTLA
$23.5M 1.26%
419,000
-1,032,301
-71% -$41.3M
2013 Q2
16 quarters
RNAC icon
20
Cartesian Therapeutics
RNAC
$187M
$21.1M 1.12%
35,333
– –
2016 Q4
2 quarters
SYRS icon
21
DELISTED
Syros Pharmaceuticals
SYRS
$20.4M 1.09%
126,895
-34,619
-21% -$5.44M
2016 Q2
4 quarters
LOXO
22
DELISTED
Loxo Oncology
LOXO
$20.1M 1.07%
251,167
-502,133
-67% -$27.8M
2014 Q3
11 quarters
AET
23
DELISTED
Aetna Inc
AET
$19.7M 1.05%
130,000
-137,000
-51% -$19.4M
2015 Q1
9 quarters
BCRX icon
24
BioCryst Pharmaceuticals
BCRX
$1.86B
$19.5M 1.04%
3,499,202
+413,966
+13% +$2.52M
2016 Q3
3 quarters
PDCO icon
25
DELISTED
Patterson Companies
PDCO
$18.5M 0.98%
+393,262
New +$17.7M
2017 Q2
0 quarters

Similar funds

Deerfield Management's Q2 2017 Portfolio in Review

As of Q2 2017, Deerfield Management held 112 positions worth $1.87B, down 28% from $2.59B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Deerfield Management withdrew a net $899M in Q2 2017, closing 27 positions and reducing 41 holdings. Its most notable exit was Vanda Pharmaceuticals, an estimated $32.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 76% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Deerfield Management opened a new position in Intersect ENT worth $33.2M.

  • Deerfield Management's largest Q2 2017 buy was Intersect ENT: 1,189,577 shares worth $33.2M.
  • Deerfield Management added most to Glaukos in Q2 2017, an estimated $30.8M increase.
  • Deerfield Management's biggest Q2 2017 reduction was Blueprint Medicines, cutting an estimated $49.3M.
  • Deerfield Management fully exited Vanda Pharmaceuticals in Q2 2017, selling an estimated $32.2M.
  • Deerfield Management's ten largest holdings make up 42% of its $1.87B portfolio in Q2 2017.
  • Deerfield Management opened 12 new positions and closed 27 in Q2 2017.
  • Deerfield Management's portfolio value fell 28% quarter-over-quarter to $1.87B.

Based on Deerfield Management's 13F filing for Q2 2017, filed 14 Aug 2017.